Skip to main content
main-content

01.12.2014 | Research | Ausgabe 1/2014 Open Access

Clinical Sarcoma Research 1/2014

Comprehensive analysis of published studies involving systemic treatment for chondrosarcoma of bone between 2000 and 2013

Zeitschrift:
Clinical Sarcoma Research > Ausgabe 1/2014
Autoren:
Annemiek M van Maldegem, Judith VMG Bovée, Hans Gelderblom
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​2045-3329-4-11) contains supplementary material, which is available to authorized users.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

HG conceived the study. AVM collected data. AVM and HG wrote the paper and JB made comments. All authors read and approved the final manuscript.

Abstract

Background

The majority of patients with chondrosarcoma of bone have an excellent overall survival after local therapy. However, in case of unresectable locally advanced or metastatic disease the outcome is poor and limited treatment options exist. Therefore we conducted a survey of clinical phase I or II trials and retrospective studies that described systemic therapy for chondrosarcoma patients.

Materials and methods

Using PubMed, clinicaltrials.gov, the Cochrane controlled trial register and American Society of Clinical Oncology (ASCO) abstracts a literature survey was conducted. From the identified items, data were collected by a systematic analysis. We limited our search to semi-recent studies published between 2000 and 2013 to include modern drugs, imaging techniques and disease evaluations.

Results

A total of 31 studies were found which met the criteria: 9 phase I trials, 11 phase II and 8 retrospective studies. In these studies 855 chondrosarcoma patients were reported. The tested drugs were mostly non-cytotoxic, either alone or in combination with another non-cytotoxic agent or chemotherapy. Currently two phase I trials, one phase IB/II trial and three phase II trials are enrolling chondrosarcoma patients.

Conclusion

Because chondrosarcoma of bone is an orphan disease it is difficult to conduct clinical trials. The meagre outcome data for locally advanced or metastatic patients indicate that new treatment options are needed. For the phase I trials it is difficult to draw conclusions because of the low numbers of chondrosarcoma patients enrolled, and at different dose levels. Some phase II trials show promising results which support further research. Retrospective studies are encouraged as they could add to the limited data available. Efforts to increase the number of studies for this orphan disease are urgently needed.
Zusatzmaterial
Authors’ original file for figure 1
13569_2014_59_MOESM1_ESM.pdf
Authors’ original file for figure 2
13569_2014_59_MOESM2_ESM.tiff
Authors’ original file for figure 3
13569_2014_59_MOESM3_ESM.docx
Authors’ original file for figure 4
13569_2014_59_MOESM4_ESM.docx
Authors’ original file for figure 5
13569_2014_59_MOESM5_ESM.docx
Authors’ original file for figure 6
13569_2014_59_MOESM6_ESM.docx
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2014

Clinical Sarcoma Research 1/2014 Zur Ausgabe

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise